News Headlines Article

Diabetes patch deal helps Zosano Pharma stick it to needles
San Francisco Business Times

Zosano Pharma Inc. is taking the shot out of the needle. The Fremont company struck a deal this week to turn Danish pharmaceutical giant Novo Nordisk’s experimental injectable type 2 diabetes drug into a patient-friendly patch. The deal could bring privately held Zosano upwards of $60 million in milestone payments, on top of undisclosed upfront cash, and another $55 million for follow-on programs.